These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 16173790)
1. Matrix metalloprotease triggered delivery of cancer chemotherapeutics from hydrogel matrixes. Tauro JR; Gemeinhart RA Bioconjug Chem; 2005; 16(5):1133-9. PubMed ID: 16173790 [TBL] [Abstract][Full Text] [Related]
2. Extracellular protease activation of chemotherapeutics from hydrogel matrices: a new paradigm for local chemotherapy. Tauro JR; Gemeinhart RA Mol Pharm; 2005; 2(5):435-8. PubMed ID: 16196497 [TBL] [Abstract][Full Text] [Related]
3. Novel composite drug delivery system for honokiol delivery: self-assembled poly(ethylene glycol)-poly(epsilon-caprolactone)-poly(ethylene glycol) micelles in thermosensitive poly(ethylene glycol)-poly(epsilon-caprolactone)-poly(ethylene glycol) hydrogel. Gong C; Shi S; Wang X; Wang Y; Fu S; Dong P; Chen L; Zhao X; Wei Y; Qian Z J Phys Chem B; 2009 Jul; 113(30):10183-8. PubMed ID: 19572675 [TBL] [Abstract][Full Text] [Related]
4. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach. Varghese OP; Sun W; Hilborn J; Ossipov DA J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915 [TBL] [Abstract][Full Text] [Related]
5. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo. Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568 [TBL] [Abstract][Full Text] [Related]
6. Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivo. Guo DD; Xu CX; Quan JS; Song CK; Jin H; Kim DD; Choi YJ; Cho MH; Cho CS Biomaterials; 2009 Sep; 30(27):4777-85. PubMed ID: 19524293 [TBL] [Abstract][Full Text] [Related]
7. Biological activity and clinical implications of the matrix metalloproteinases. Rydlova M; Holubec L; Ludvikova M; Kalfert D; Franekova J; Povysil C; Ludvikova M Anticancer Res; 2008; 28(2B):1389-97. PubMed ID: 18505085 [TBL] [Abstract][Full Text] [Related]
8. Development of a temperature-sensitive composite hydrogel for drug delivery applications. Ramanan RM; Chellamuthu P; Tang L; Nguyen KT Biotechnol Prog; 2006; 22(1):118-25. PubMed ID: 16454501 [TBL] [Abstract][Full Text] [Related]
9. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis]. Masson V Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905 [TBL] [Abstract][Full Text] [Related]
10. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Ta HT; Dass CR; Larson I; Choong PF; Dunstan DE Biomaterials; 2009 Jul; 30(21):3605-13. PubMed ID: 19345993 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins. Lalloo A; Chao P; Hu P; Stein S; Sinko PJ J Control Release; 2006 May; 112(3):333-42. PubMed ID: 16650910 [TBL] [Abstract][Full Text] [Related]
12. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Cai KQ; Yang WL; Capo-Chichi CD; Vanderveer L; Wu H; Godwin AK; Xu XX Mol Carcinog; 2007 Feb; 46(2):130-43. PubMed ID: 17131304 [TBL] [Abstract][Full Text] [Related]
14. Repression of matrix metalloproteinase gene expression by ginsenoside Rh2 in human astroglioma cells. Kim SY; Kim DH; Han SJ; Hyun JW; Kim HS Biochem Pharmacol; 2007 Dec; 74(11):1642-51. PubMed ID: 17880928 [TBL] [Abstract][Full Text] [Related]
15. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme]. Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Park HJ; Chung HJ; Min HY; Park EJ; Hong JY; Kim WB; Kim SH; Lee SK Biochem Pharmacol; 2005 Dec; 71(1-2):21-31. PubMed ID: 16271263 [TBL] [Abstract][Full Text] [Related]
17. Polymorphonuclear leukocytes promote neurotoxicity through release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha. Nguyen HX; O'Barr TJ; Anderson AJ J Neurochem; 2007 Aug; 102(3):900-12. PubMed ID: 17561941 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of a benz[f]indole-4,9-dione analog on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells. Park HJ; Lee HJ; Min HY; Chung HJ; Suh ME; Park-Choo HY; Kim C; Kim HJ; Seo EK; Lee SK Eur J Pharmacol; 2005 Dec; 527(1-3):31-6. PubMed ID: 16309669 [TBL] [Abstract][Full Text] [Related]
19. A novel controlled local drug delivery system for inner ear disease. Paulson DP; Abuzeid W; Jiang H; Oe T; O'Malley BW; Li D Laryngoscope; 2008 Apr; 118(4):706-11. PubMed ID: 18182968 [TBL] [Abstract][Full Text] [Related]
20. QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase. Jamloki A; Karthikeyan C; Hari Narayana Moorthy NS; Trivedi P Bioorg Med Chem Lett; 2006 Jul; 16(14):3847-54. PubMed ID: 16682189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]